Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin. 2021; 71: 209-249
- Gastric Cancer : Epidemiology , Risk Factors , Classification , Genomic Characteristics and Treatment Strategies.Int J Mol Sci. 2020; 21: 4012
- Surgical Management of Early Esophageal Cancer.Surg Clin North Am. 2021; 101: 427-441
- A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer.Gastric Cancer. 2012; 15: 38-47
- Esophageal Cancer.Gastroenterol Clin North Am. 2016; 45: 399-412
- Trends in the incidence and survival of patients with esophageal cancer: A SEER database analysis.Thorac Cancer. 2020; 11: 1121
- Gastric Cancer Epidemiology.Gastrointest Endosc Clin North Am. 2021; 31: 425-439
- Trends in esophageal cancer incidence by histology, United States, 1998-2003.Int J Cancer. 2008; 123: 1422-1428
- Obesity and cancer risk: Emerging biological mechanisms and perspectives.Metab Clin Exp. 2019; 92: 121-135
- The Epidemiology of Esophageal Adenocarcinoma.Gastroenterology. 2018; 154: 390-405
- Esophageal Cancer - American Family Physician.(Available at:) (Accessed April 2, 2022)
- Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention.Cancer Epidemiol Biomarkers Prev. 2014; https://doi.org/10.1158/1055-9965.EPI-13-1057
- Epidemiology of gastric cancer: global trends, risk factors and prevention.Gastroenterol Rev. 2019; 14
- The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma.Acta Pathol Microbiol Scand. 1965; 1: 31-49
- Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value.World J Gastroenterol. 2014; 20: 5679-5684
- Adenocarcinoma of the Esophagogastric Junction Results of Surgical Therapy Based on Anatomical/Topographic Classification in 1,002 Consecutive Patients.Ann Surg. 2000; 232: 353-361
- Esophageal cancer: An update.Int J Surg. 2010; 8: 417-422
- Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy.Gastroenterology. 2018; 154: 421-436
- Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma.Gastroenterology. 1982; 82: 228-231
- AJCC Cancer Staging Manual Eighth Edition.(Available at:) (Accessed April 20, 2022)
- Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer.J Thorac Oncol. 2017; 12: 36-42
- Esophageal Cancer: Tumor-Node-Metastasis Staging.Radiol Clin North Am. 2021; 59: 219-229
- Accuracy of endoscopic ultrasound in esophageal cancer staging.J Thorac Dis. 2019; 11: S1602-S1609
- New TNM staging system for esophageal cancer: What chest radiologists need to know.Radiographics. 2014; 34: 1722-1740
- Recent Advances in the Diagnosis, Staging, Treatment, and Prognosis of Advanced Gastric Cancer: A Literature Review.Front Med. 2021; 8: 744839
- Low impact of staging EUS for determining surgical resectability in esophageal cancer.Surg Endosc. 2012; https://doi.org/10.1007/s00464-012-2254-z
- Endoscopic options for early stage esophageal cancer.J Gastrointest Oncol. 2015; 6: 20-30
- Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative.J Am Coll Surg. 2015; 220: 48-56
- Accuracy of EUS and CT imaging in preoperative gastric cancer staging.J Surg Oncol. 2015; 111: 1016-1020
- Selection of patients with gastric adenocarcinoma for laparoscopic staging.Am J Surg. 2006; 191: 134-138
- AJCC Cancer Staging Manual.in: Amin M.B. Edge S.B. Greene F.L. AJCC cancer staging Manual. 8ht edition. Springer International Publishing, Chicago, IL2017: 185-202
- Surgical treatment of esophageal cancer in the era of multimodality management.Ann N Y Acad Sci, 2018https://doi.org/10.1111/nyas.13677
- Transhiatal versus transthoracic esophagectomy for esophageal cancer.World J Gastroenterol. 2010; 16: 3804
- Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial.Ann Surg. 2007; 246: 992-1000
- Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.N Engl J Med. 2002; 347: 1662-1669
- En bloc vs transhiatal esophagectomy for stage T3 N1 adenocarcinoma of the distal esophagus.Arch Surg. 2004; 139: 627-633
- Comparative outcomes of transthoracic versus transhiatal esophagectomy.Surgery. 2021; 170: 263-270
- Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: A meta-analysis META-ANALYSIS.World J Gastroenterol. 2014; 20: 10183-10192
- Prognostic Value of Lymph Node Yield on Overall Survival in Esophageal Cancer Patients: A Systematic Review and Meta-analysis.Ann Surg. 2019; 269: 261-268
- Predicting systemic disease in patients with esophageal cancer after esophagectomy a multinational study on the significance of the number of involved lymph nodes.Ann Surg. 2008; 248: 979-984
- Lymphadenectomy and health-related quality of life after oesophageal cancer surgery: a nationwide, population-based cohort study.BMJ Open. 2016; https://doi.org/10.1136/bmjopen-2016-012624
- Esophageal and Esophagogastric Junction Cancers (Version 2.2022).(Available at:) (Accessed May 9, 2022)
- Updates on Management of Gastric Cancer.Curr Oncol Rep. 2019; 21https://doi.org/10.1007/s11912-019-0820-4
- Gastric Cancer (Version 2.2022).(Available at:) (Accessed May 9, 2022)
- Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.Lancet Oncol. 2010; 11: 439-449
- D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial.Eur J Cancer. 2021; 150: 10-22
- Selective lymphadenectomy of para-aortic lymph nodes for advanced gastric cancer.Oncol Rep. 2009; 22: 509-514
- Extent of lymph node dissection for adenocarcinoma of the stomach.Cochrane Database Syst Rev. 2015; 2015https://doi.org/10.1002/14651858.CD001964.PUB4/MEDIA/CDSR/CD001964/IMAGE_N/NCD001964-CMP-002-02.PNG
- Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.Lancet. 2012; 379: 1887-1892
- Minimally invasive versus open esophagectomy: meta-analysis of outcomes.Dig Dis Sci. 2010; 55: 3031-3040
- Comparison of the Outcomes Between Open and Minimally Invasive Esophagectomy.Ann Surg. 2007; 245: 232
- Comparing Perioperative Mortality and Morbidity of Minimally Invasive Esophagectomy Versus Open Esophagectomy for Esophageal Cancer: A Nationwide Retrospective Analysis.Ann Surg. 2021; 274: 324-330
- Minimally invasive oesophagectomy versus open esophagectomy for resectable esophageal cancer: a meta-analysis.World J Surg Oncol. 2016; 14https://doi.org/10.1186/S12957-016-1062-7
- Minimally Invasive Versus Open Esophageal Resection: Three-year Follow-up of the Previously Reported Randomized Controlled Trial: the TIME Trial.Ann Surg. 2017; 266: 232-236
- Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial.Ann Surg. 2019; 269: 621-630
- Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma: Early Results of a Multicenter Randomized Controlled Trial: The RAMIE Trial.Ann Surg. 2022; 275: 646-653
- Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial.JAMA Surg. 2022; 157: 9-17
- Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial.JAMA Oncol. 2019; 5: 506-513
- Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial.Ann Surg. 2005; 241: 232-237
- Robotic versus laparoscopic gastrectomy for gastric cancer: The largest meta-analysis.Int J Surg. 2020; 82: 210-228
- Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma.Gastric Cancer. 2017; https://doi.org/10.1007/s10120-016-0679-0
- Endoscopic Resection of Gastric Cancer.Gastrointest Endosc Clin North Am. 2021; 31: 563-579
- Propensity score-matched comparison of short- and long-term outcomes between surgery and endoscopic submucosal dissection (ESD) for intestinal type early gastric cancer (EGC) of the middle and lower third of the stomach: a European tertiary referral center experience.Surg Endosc. 2021; 35: 2592-2600
- Long-term outcome comparison of endoscopic resection and surgery in early gastric cancer meeting the absolute indication for endoscopic resection.Gastrointest Endosc. 2015; 81: 333-341.e1
- EMR/ESD: Techniques, Complications, and Evidence.Curr Gastroenterol Rep. 2020; https://doi.org/10.1007/s11894-020-00777-z
- Japanese gastric cancer treatment guidelines 2018 (5th edition) Preface to the English version.Gastric Cancer. 2021; https://doi.org/10.1007/s10120-020-01042-y
- Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.Endoscopy. 2015; 47: 829-854
- Endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal tumors: A meta-analysis.World J Gastroenterol. 2014; 20: 8282-8287
- AGA Institute Clinical Practice Update: Endoscopic Submucosal Dissection in the United States.Clin Gastroenterol Hepatol. 2019; 17: 16-25.e1
- Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer.Dig Endosc. 2020; https://doi.org/10.1111/den.13654
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.World J Gastroenterol. 2016; 22: 1114
- Chemotherapy for advanced gastric cancer.Cochrane Database Syst Rev. 2017; 2017https://doi.org/10.1002/14651858.CD004064.PUB4/MEDIA/CDSR/CD004064/IMAGE_N/NCD004064-CMP-010-06.PNG
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages.Ann Surg Oncol. 2022; 29: 3170-3186
- Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis.J Clin Oncol. 2019; 37: 2028-2040
- Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials.Eur J Surg Oncol. 2021; 47: 2757-2767
- GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study.BMC Cancer. 2014; 14
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II).BMC Cancer. 2019; 19https://doi.org/10.1186/S12885-019-5640-2
- Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence - Full Text View - ClinicalTrials.gov.(Available at:) (Accessed May 9, 2022)
- Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III “PREVENT”- (FLOT9) trial of the AIO/CAOGI/ACO.BMC Cancer. 2021; 21https://doi.org/10.1186/S12885-021-08872-8
- Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.Lancet. 2002; 359: 1727-1733
- Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.J Clin Oncol. 2009; 27: 5062-5067
- Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer.N Engl J Med. 2009; 339: 1979-1984
- Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.Lancet Oncol. 2007; 8: 226-234
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer From the Departments of Medicine (D. Vol 355.; 2006.(Available at:) (Accessed April 20, 2022)
- Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial.J Clin Oncol. 2011; 29: 1715-1721
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.Lancet. 2019; 393: 1948-1957
- Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008).Am J Clin Oncol. 2009; 27: 4515
- Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer.N Engl J Med. 2012; 366: 2074-2084
- Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.J Clin Oncol. 2021; 39: 1995-2004
- Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.Lancet Oncol. 2018; 19: 616-628
- CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.BMC Cancer. 2018; 18https://doi.org/10.1186/S12885-018-4770-2
- Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.J Clin Oncol. 2012; 30: 268-273
- A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial.Ann Oncol. 2021; 32: 368-374
- TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).BMC Cancer. 2015; 15
- TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.Ann Surg Oncol. 2017; 24: 2252-2258
- ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).BMC Cancer. 2016; 16https://doi.org/10.1186/S12885-016-2564-Y
- ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS).BMC Cancer. 2017; 17https://doi.org/10.1186/S12885-017-3386-2
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.Ann Oncol. 2008; 19: 1523-1529
- Perspectives of HER2-targeting in gastric and esophageal cancer.Expert Opin Investig Drugs. 2017; 26: 531-540
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010; 376: 687-697
- Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.Lancet Oncol. 2022; 23: 259-269
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet. 2014; 383: 31-39
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.Lancet Oncol. 2014; 15: 1224-1235
- Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.Am J Clin Oncol. 2020; 38: 4501
- Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.Am J Clin Oncol. 2020; 38: 4502
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.J Clin Oncol. 2020; 38: 4138-4148
- Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.Am J Clin Oncol. 2021; 39: 204
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2017; 390: 2461-2471
Article info
Publication history
Published online: November 03, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
